# Lung Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/lung-therapeutics

- Industry: Pharmaceuticals
- Headquarters: Austin, US
- Website: www.lungtx.com
- Total disclosed funding: $53M
- Latest round: Series C (Oct 31, 2019)
- Investors on record: 2

## About

Lung Therapeutics, Inc. focuses on innovative therapies for treating lung fibrosis, especially Idiopathic Pulmonary Fibrosis (IPF), through advanced dual-mechanism treatments that aim to enhance patient health outcomes.Founded in 2012 and headquartered in Austin, US, Lung Therapeutics, Inc. specializes in developing therapies for fibrotic diseases. The firm has engaged in 10 deals, with its most recent funding round occurring on March 14, 2022, where it raised USD 10.07 mn. The company is led by CEO Brian Windsor, whose leadership has been pivotal in guiding its research and development efforts.Lung Therapeutics specializes in innovative therapies aimed at treating fibrosis, with a focus on multi-pathway approaches that address both anti-fibrotic and regenerative needs. The company's flagship product, LTI-03, is a groundbreaking therapy designed specifically for patients with Idiopathic Pulmonary Fibrosis (IPF). This dual-mechanism treatment works to improve lung function, reduce scarring, and promote homeostasis, thereby enhancing the overall quality of life for patients suffering from this debilitating condition. Lung Therapeutics targets various geographical markets, including North America and Europe, where there is a significant prevalence of fibrotic diseases and a need for advanced treatment options. The end users of these therapies primarily include healthcare providers who administer these treatments, as well as patients seeking improved management of their fibrotic conditions.Lung Therapeutics generates revenue through various channels, primarily focusing on partnerships with healthcare providers and institutions that utilize their therapies in clinical settings. Revenue is derived from the sale of their proprietary treatments, such as LTI-03, which are integrated into medical care for patients with IPF. The structure of these transactions typically involves direct sales to hospitals and clinics, where healthcare professionals administer the therapies to patients. The company may also engage in research partnerships with pharmaceutical companies, enhancing revenue through collaborative projects aimed at advancing fibrosis treatment solutions. Such partnerships allow for shared research and development costs, thereby facilitating access to broader markets while maximizing the impact of their multi-pathway therapies.Lung Therapeutics is focused on expanding its product offerings and geographic reach. The company plans to launch new therapies and enhance its existing product line by continuing to innovate in the fibrosis treatment space. Following its recent funding round in March 2022, which raised USD 10.07 mn, Lung Therapeutics will utilize these funds to support the development of upcoming products and expand its presence in North America and Europe. This strategic expansion aims to address the growing demand for effective therapies in markets where fibrotic diseases are prevalent.

## Funding rounds

- Series C, Oct 31, 2019, $2.5M — Bios Partners
- Series C, May 20, 2019, $36M — Bios Partners
- Series B, May 18, 2017, $11M — Bios Partners, UT Horizon Fund
- Series B, Feb 24, 2017, $2.4M — Bios Partners, UT Horizon Fund
- Series B, Mar 1, 2016, $1.1M — Bios Partners, UT Horizon Fund

## Investors

- Bios Partners (https://capitalatlas.ai/funds/bios-partners) — Series B, Series C
- UT Horizon Fund (https://capitalatlas.ai/funds/ut-horizon-fund) — Series B